SARS-CoV-2 Antibody Response Following SPUTNIK V Vaccination in Healthcare Workers From a Hospital in Argentina: Preliminary Results

2021 ◽  
Author(s):  
Angela Gentile ◽  
Vanesa Edelvais Castellano ◽  
Natacha Weinberger ◽  
Anabella Cecilia Pacchiotti ◽  
Sofia María Diana Menendez ◽  
...  
Keyword(s):  
Antibody Response ◽  
Healthcare Workers ◽  
Preliminary Results

Antibody response to the influenza vaccine in healthcare workers

Vaccine ◽  
2012 ◽  
Vol 30 (2) ◽  
pp. 436-441 ◽  
Author(s):  
Ema Sacadura-Leite ◽  
Antonio Sousa-Uva ◽  
Helena Rebelo-de-Andrade
Keyword(s):  
Antibody Response ◽  
Influenza Vaccine ◽  
Healthcare Workers

scholarly journals Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers

2021 ◽  
Author(s):  
Marie Tré-Hardy ◽  
Roberto Cupaiolo ◽  
Emmanuelle Papleux ◽  
Alain Wilmet ◽  
Alexandra Horeanga ◽  
...  
Keyword(s):  
Antibody Response ◽  
Healthcare Workers

scholarly journals EVALUATION OF ANTIBODY RESPONSE AFTER COVID‐19 VACCINATION OF HEALTHCARE WORKERS

2021 ◽  
Author(s):  
Elif Bilge Uysal ◽  
Sibel Gümüş ◽  
Bayhan Bektöre ◽  
Hale Bozkurt ◽  
Ayşegül Gözalan
Keyword(s):  
Antibody Response ◽  
Healthcare Workers

Association ofHLA-G3′ untranslated region polymorphisms with antibody response againstPlasmodium falciparumantigens: preliminary results

2013 ◽  
Vol 82 (1) ◽  
pp. 53-58 ◽  
Author(s):  
A. Sabbagh ◽  
D. Courtin ◽  
J. Milet ◽  
J. D. Massaro ◽  
E. C. Castelli ◽  
...  
Keyword(s):  
Antibody Response ◽  
Untranslated Region ◽  
Preliminary Results

scholarly journals mRNA SARS-CoV-2 Immunization Confers Robust Antibody Response in Occupational Healthcare Workers and Fosters Workplace Safety

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Bart O. Iddins ◽  
Mark H. Waugh ◽  
Brandon Buck ◽  
Tracey Cato ◽  
Adam Partin ◽  
...  
Keyword(s):  
Antibody Response ◽  
Healthcare Workers ◽  
Workplace Safety ◽  
Occupational Healthcare

scholarly journals Co-Occurrence of SARS-CoV-2 Infection and Inactivated SARS-CoV-2 Vaccination among Healthcare Workers

2021 ◽  
Vol 2021 ◽  
pp. 1-4
Author(s):  
Cucunawangsih Cucunawangsih ◽  
Ratna Sari Wijaya ◽  
Nata Pratama Hardjo Lugito ◽  
Ivet Suriapranata
Keyword(s):  
Antibody Response ◽  
Healthcare Workers ◽  
Vaccination Campaign

The presented cases describe the concurrent SARS-CoV-2 infection and inactivated SARS-CoV-2 vaccination among eight healthcare workers (HCWs). These cases highlighted the importance of broad hospital screening during the COVID-19 vaccination campaign. Further study regarding the durability of antibody response induced by infection and first-dose vaccination is required to determine the appropriate time for giving a second dose of inactivated SARS-CoV-2 vaccine among these cases.

scholarly journals Effect Monitoring and Insights from Vaccination program of Healthcare Workforce from a tertiary level hospital in India against SARS-CoV-2

2021 ◽  
Author(s):  
Rajat Ujjainia ◽  
Akansha Tyagi ◽  
Viren Sardana ◽  
Salwa Naushin ◽  
Nitin Bhatheja ◽  
...  
Keyword(s):  
Antibody Response ◽  
Neutralizing Antibodies ◽  
Healthcare Workers ◽  
Protein S ◽  
Maximum Increase ◽  
Post Vaccination ◽  
Neutralizing Activity ◽  
Effect Monitoring ◽  
Antibody Levels ◽  
Level Hospital

AbstractThe Oxford-Astra Zeneca COVID 19 vaccine (AZD1222 or ChAdOx1) is locally manufactured as Covishield by Serum Institute, Pune, India. In a group of 307 healthcare workers administered Covishield, we report measured antibody response to SARS-CoV-2 directed against the spike protein (S-antigen) at days 0, 7, 14, 28 and 45, with second dose on day 28 for all except 20 subjects who did not receive a second dose. In 129 subjects (42%) who had already developed antibodies to SARS-CoV-2 at day 0 (before immunization), it was observed that antibody response was significantly higher at each time point, with the maximum increase seen between days 0 and 7. The antibody levels and neutralizing activity in these subjects had peaked by day 28 and the second dose did not lead to further increase. Data from 9 subjects who were seropositive at baseline and received only one dose was similar to those who received both doses. In contrast the baseline sero-negative group (n=178) started developing antibody response only after 14 days or later. Administration of the second dose was associated with further increase in antibody levels at day 45 compared to day 28, with marked increase in neutralizing activity. In baseline seronegative subjects, who did not take the vaccine at day 28 (n=11), the antibody levels increased by about 2.5 folds between days 28 and 45, with minimal change in the neutralizing antibodies. In general, vaccination was well tolerated, and there were no group specific differences in post-vaccination symptomatology. Our data suggests that ChAdOx1 is highly immunogenic, particularly so where previous SARS CoV2 antibody-response is established. In such subjects, a single dose may be sufficient but in absence of such determination, both doses are required.

scholarly journals Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2

2021 ◽  
Vol 10 (18) ◽  
pp. 4204
Author(s):  
Marcello Salvaggio ◽  
Federica Fusina ◽  
Filippo Albani ◽  
Maurizio Salvaggio ◽  
Rasula Beschi ◽  
...  
Keyword(s):  
Antibody Response ◽  
Healthcare Workers ◽  
Antibody Concentration ◽  
Clinical Documentation ◽  
Receptor Binding Domain ◽  
Effective Number ◽  
Significant Difference ◽  
Before And After ◽  
Previous Infection ◽  
Antibody Levels

The Pfizer/BioNtech Comirnaty vaccine (BNT162b2 mRNA COVID-19) against SARS-CoV-2 is currently in use in Italy. Antibodies to evaluate SARS-CoV-2 infection prior to administration are not routinely tested; therefore, two doses may be administered to asymptomatic previously exposed subjects. The aim of this study is to assess if any difference in antibody concentration between subjects exposed and not exposed to SARS-CoV-2 prior to BNT162b2 was present after the first dose and after the second dose of vaccine. Data were retrospectively collected from the clinical documentation of 337 healthcare workers who underwent SARS-CoV-2 testing before and after BNT162b2. Total anti RBD (receptor-binding domain) antibodies against SARS-CoV-2′s spike protein were measured before and 21 days after the first dose, and 12 days after the second dose of BNT162b2. Twenty-one days after the first dose, there was a statistically significant difference in antibody concentration between the two groups, which was also maintained twelve days after the second dose. In conclusion, antibody response after receiving BNT162b2 is greater in subjects who have been previously exposed to SARS-CoV-2 than in subjects who have not been previously exposed to the virus, both after 21 days after the first dose and after 12 days from the second dose. Antibody levels, 21 days after the first dose, reached a titer considered positive by the test manufacturer in the majority of subjects who have been previously infected with SARS-CoV-2. Evaluating previous infection prior to vaccination in order to give the least effective number of doses should be considered.

Sign in / Sign up

Export Citation Format

Share Document